Transarterial Radioembolization (TARE) Agents beyond Y-90-Microspheres - Université de Rennes Access content directly
Journal Articles BioMed Research International Year : 2018

Transarterial Radioembolization (TARE) Agents beyond Y-90-Microspheres


Liver malignancies, either primary tumours (mainly hepatocellular carcinoma and cholangiocarcinoma) or secondary hepatic metastases, are a major cause of death, with an increasing incidence. Among them, hepatocellular carcinoma (HCC) presents with a dark prognosis because of underlying liver diseases and an often late diagnosis. A curative surgical treatment can therefore only be proposed in 20 to 30% of the patients. However, new treatment options for intermediate to advanced stages, such as internal radionuclide therapy, seem particularly attractive. Transarterial radioembolization (TARE), which consists in the use of intra-arterial injection of a radiolabelled embolising agent, has led to very promising results. TARE with Y-90-loaded microspheres is now becoming an established procedure to treat liver tumours, with two commercially available products (namely, SIR-Sphere (R) and TheraSphere (R)). However, this technology remains expensive and is thus not available everywhere. The aim of this review is to describe TARE alternative technologies currently developed and investigated in clinical trials, with special emphasis on HCC.
Fichier principal
Vignette du fichier
1435302.pdf (1.9 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-02049234 , version 1 (12-07-2019)





C. Bouvry, X. Palard, J. Edeline, V. Ardisson, P. Loyer, et al.. Transarterial Radioembolization (TARE) Agents beyond Y-90-Microspheres. BioMed Research International , 2018, 2018, pp.1435302. ⟨10.1155/2018/1435302⟩. ⟨hal-02049234⟩
84 View
140 Download



Gmail Facebook X LinkedIn More